182 related articles for article (PubMed ID: 38753434)
61. Proteomic, miRNA and bacterial biomarker patterns in atopic dermatitis patients and their course upon anti-IL-4Rα therapy.
Pažur K; Francuzik W; El-Mahmoud H; Kraft M; Worm M
J Eur Acad Dermatol Venereol; 2024 Feb; ():. PubMed ID: 38379385
[TBL] [Abstract][Full Text] [Related]
62. Recent considerations in the use of recombinant interferon gamma for biological therapy of atopic dermatitis.
Brar K; Leung DY
Expert Opin Biol Ther; 2016; 16(4):507-14. PubMed ID: 26694988
[TBL] [Abstract][Full Text] [Related]
63. A Therapeutic Renaissance - Emerging Treatments for Atopic Dermatitis.
Na CH; Baghoomian W; Simpson EL
Acta Derm Venereol; 2020 Jun; 100(12):adv00165. PubMed ID: 32419031
[TBL] [Abstract][Full Text] [Related]
64. Advances in atopic dermatitis and urticarial in 2016.
Honda T; Nomura T; Kabashima K
J Allergy Clin Immunol; 2017 Aug; 140(2):369-376. PubMed ID: 28652155
[TBL] [Abstract][Full Text] [Related]
65. The Impact of Psoriasis and Atopic Dermatitis on Quality of Life: A Literature Research on Biomarkers.
Balato A; Zink A; Babino G; Buononato D; Kiani C; Eyerich K; Ziehfreund S; Scala E
Life (Basel); 2022 Dec; 12(12):. PubMed ID: 36556392
[TBL] [Abstract][Full Text] [Related]
66. Atopic Dermatitis Biomarkers and the Movement Toward Personalized Treatment.
Hassan S; Hamideh N; Poulos C; Cheema S; Rangwani S; Lio PA
Dermatitis; 2021 Oct; 32(1S):S8-S14. PubMed ID: 34677167
[TBL] [Abstract][Full Text] [Related]
67. Atopic Dermatitis: Beyond the Skin and Into the Gut.
Sadowsky RL; Sulejmani P; Lio PA
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685600
[TBL] [Abstract][Full Text] [Related]
68. Skewed inflammation is associated with aberrant interleukin-37 signaling pathway in atopic dermatitis.
Hou T; Tsang MS; Chu IM; Kan LL; Hon KL; Leung TF; Lam CW; Wong CK
Allergy; 2021 Jul; 76(7):2102-2114. PubMed ID: 33569791
[TBL] [Abstract][Full Text] [Related]
69. Complementary, Alternative and Integrative Medicine for Childhood Atopic Dermatitis.
Hon KL; Leung AKC; Leung TNH; Lee VWY
Recent Pat Inflamm Allergy Drug Discov; 2017; 11(2):114-124. PubMed ID: 29189188
[TBL] [Abstract][Full Text] [Related]
70. Exogenous factors in the pathogenesis of atopic dermatitis: Irritants and cutaneous infections.
Yue H; Umehara Y; Trujillo-Paez JV; Peng G; Nguyen HLT; Chieosilapatham P; Kiatsurayanon C; Song P; Okumura K; Ogawa H; Ikeda S; Niyonsaba F
Clin Exp Allergy; 2021 Mar; 51(3):382-392. PubMed ID: 33394511
[TBL] [Abstract][Full Text] [Related]
71. New treatments in atopic dermatitis.
Puar N; Chovatiya R; Paller AS
Ann Allergy Asthma Immunol; 2021 Jan; 126(1):21-31. PubMed ID: 32818591
[TBL] [Abstract][Full Text] [Related]
72. Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and Staphylococcus aureus colonization.
Broccardo CJ; Mahaffey S; Schwarz J; Wruck L; David G; Schlievert PM; Reisdorph NA; Leung DY
J Allergy Clin Immunol; 2011 Jan; 127(1):186-93, 193.e1-11. PubMed ID: 21211653
[TBL] [Abstract][Full Text] [Related]
73. Therapeutic targeting of the IL-13 pathway in skin inflammation.
Tubau C; Puig L
Expert Rev Clin Immunol; 2021 Jan; 17(1):15-25. PubMed ID: 33275064
[No Abstract] [Full Text] [Related]
74. Identification of Cofilin-1 as a novel biomarker of atopic dermatitis using iTRAQ quantitative proteomics.
Zhou X; Xiao B; Zeng J; Zhou L; Wang X; Zhao S; Li X; Zhang H; Su Y; Zhao Z; Li X
J Clin Lab Anal; 2022 Nov; 36(11):e24751. PubMed ID: 36305098
[TBL] [Abstract][Full Text] [Related]
75. Proteomic signatures of neuroinflammation in Alzheimer's disease, multiple sclerosis and ischemic stroke.
Thygesen C; Larsen MR; Finsen B
Expert Rev Proteomics; 2019 Jul; 16(7):601-611. PubMed ID: 31220951
[No Abstract] [Full Text] [Related]
76. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
Kraft M; Worm M
Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
[TBL] [Abstract][Full Text] [Related]
77. Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis.
Silverberg JI; Simpson EL; Armstrong AW; de Bruin-Weller MS; Irvine AD; Reich K
Am J Clin Dermatol; 2022 Jan; 23(1):1-11. PubMed ID: 34699031
[TBL] [Abstract][Full Text] [Related]
78. An evaluation of abrocitinib for moderate-to-severe atopic dermatitis.
Labib A; Yosipovitch G
Expert Rev Clin Immunol; 2022 Nov; 18(11):1107-1118. PubMed ID: 36173402
[TBL] [Abstract][Full Text] [Related]
79. Glycoproteomic analysis of plasma from patients with atopic dermatitis: CD5L and ApoE as potential biomarkers.
Kim WK; Hwang HR; Kim DH; Lee PY; In YJ; Ryu HY; Park SG; Bae KH; Lee SC
Exp Mol Med; 2008 Dec; 40(6):677-85. PubMed ID: 19116453
[TBL] [Abstract][Full Text] [Related]
80. Topical agents for the treatment of atopic dermatitis.
Diaz A; Guttman-Yassky E
Expert Rev Clin Immunol; 2019 Apr; 15(4):369-382. PubMed ID: 30587053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
